Assessing the effect of brimonidine gel on the redness remained after pimples

Comparison of the effect of Brimonidine 0.33% gel and placebo on the clinical erythema score in post-acne erythema patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140212016557N11

Enrollment

Registered

2023-07-31

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-acne erythema. Other acne

Interventions

Intervention 1: Intervention group: Brimonidine 0.33% gel (Janus, Tehran, Iran) is applied once overnight on the face. Intervention 2: Control group: Lubricant gel (Razak, Tehran, Iran) is applied onc

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Patients between 18 and 45 years of age Post-acne erythema after successful treatment of acne vulgaris

Exclusion criteria

Exclusion criteria: pregnancy lactation depression cerebral or coronary artery insufficiency Raynaud’s phenomenon orthostatic hypotension thromboangiitis obliterans scleroderma Sjögren’s syndrome severe or unstable cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Clinician score of post-acne erythema. Timepoint: Before intervention, 4 and 8 weeks after starting intervention, and 1 months after treatment cessation. Method of measurement: 5-point clinical score, defined as: 0=clear with no erythema, 1 = almost clear or slight redness, 2 = mild or definite redness, 3 = moderate or marked redness, 4 = severe or fiery redness.	—

Secondary

Measure	Time frame
Skin erythema index. Timepoint: Before intervention, 4 and 8 weeks after starting intervention, and 1 months after treatment cessation. Method of measurement: Dermacatch instrument.;Patient self-assessment of post acne erythema treatment. Timepoint: 4 and 8 weeks after starting intervention, and 1 months after treatment cessation. Method of measurement: 4-point patient assessment of treatment result expressedas: a. No improvement, b. Mild improvement, c. Good improvement, d. Excellent improvement.;Quality of life. Timepoint: before intervention and 1 months after cessation of treatment. Method of measurement: Dermatology Life Quality index questionnaire Persian version.	—

Measure

Time frame

Skin erythema index. Timepoint: Before intervention, 4 and 8 weeks after starting intervention, and 1 months after treatment cessation. Method of measurement: Dermacatch instrument.;Patient self-assessment of post acne erythema treatment. Timepoint: 4 and 8 weeks after starting intervention, and 1 months after treatment cessation. Method of measurement: 4-point patient assessment of treatment result expressedas: a. No improvement, b. Mild improvement, c. Good improvement, d. Excellent improvement.;Quality of life. Timepoint: before intervention and 1 months after cessation of treatment. Method of measurement: Dermatology Life Quality index questionnaire Persian version.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMozhdeh Sepaskhah

Shiraz University of Medical Sciences

sepaskhah@sums.ac.ir+98 71 3212 5239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026